Gary GlickFounder and Executive Chairman of the Board at IFM
Gary D. Glick has over 25 years of experience in leading the discovery and development of therapies in biopharmaceutical companies and academic institutions. Prior to founding IFM, Gary founded Lycera Corp to discover breakthrough medicines for autoimmune diseases and cancer. Serving first as president, then as chief science officer, he built the R&D team and raised over $40 MM in equity financing to support the company. Under his direction, Lycera initiated six discovery programs; partnered three of these programs with Merck & Co. in deals collectively valued at over $600 MM; advanced LYC-30937, a modulator of the mitochondrial ATPase based directly on research from his academic lab, into clinical trials for inflammatory bowel disease; and established and drove Lycera’s immune-oncology platform. This pipeline formed the basis of a $105 MM option deal that provides Celgene Corporation the opportunity to acquire Lycera after completion of certain clinical milestones.
Gary started his career as a faculty member at the University of Michigan in Ann Arbor in 1990, where he is now the Werner E. Bachmann emeritus professor of chemistry. He still maintains an active lab focused on metabolic control in the immune system and the development of new drugs for the treatment of autoimmunity and cancer.
Gary obtained his Ph.D. degree in organic chemistry from Columbia University in 1988 and was an NIH postdoctoral fellow at Harvard University. He is the author of over 100 papers and the inventor on 28 issued U.S. patents.